The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Positron Emission Tomography (PET) Nuclear Medicine Market Expected To Change From 2026 To 2030?
The positron emission tomography (pet) nuclear medicine market has seen rapid expansion in recent years. This market is anticipated to grow from $13.16 billion in 2025 to $15.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.5%. The historical growth of this market is attributable to rising cancer diagnosis rates, an increase in nuclear medicine facilities, the extensive use of f-18 radiotracers, growth in cardiology imaging applications, and advancements in radiopharmaceutical production.
The positron emission tomography (PET) nuclear medicine market size is projected to experience substantial growth in the upcoming years. It is foreseen to expand to $25.7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This expansion over the forecast period is attributable to heightened investments in molecular imaging, an increasing need for personalized medicine diagnostics, the broadening of neurological imaging applications, developments in radiotracer technology, and the rising uptake of hybrid imaging systems. Noteworthy trends during the forecast period include the increasing adoption of sophisticated radiotracers, the expanding utilization of PET imaging in oncology, the growing integration of PET with CT and MRI systems, the proliferation of precision diagnostic imaging applications, and a stronger emphasis on early disease detection.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
What Key Factors Are Affecting The Positron Emission Tomography (PET) Nuclear Medicine Market Demand?
The growing incidence of chronic diseases is projected to stimulate the expansion of the positron emission tomography (PET) nuclear medicine market moving forward. A chronic disease refers to an enduring health issue that commonly lasts for at least three months, potentially requiring ongoing medical attention or limiting everyday functions. The escalation in chronic diseases stems from various factors, including an aging population, inadequate physical activity, unhealthy eating habits, and environmental risks. PET nuclear medicine aids in the management of chronic diseases by offering advanced imaging solutions that allow for their early detection, precise diagnosis, and continuous monitoring. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, forecast that by 2050, new cancer cases would exceed 35 million, signifying a 77% increase from the approximate 20 million cases in 2022. Therefore, the heightened prevalence of chronic diseases is a primary catalyst for the growth of the positron emission tomography (PET) nuclear medicine market.
Which Segment Categories Are Included In The Positron Emission Tomography (PET) Nuclear Medicine Market Segment Analysis?
The positron emission tomography (pet) nuclear medicine market covered in this report is segmented –
1) By Type: F-18, Rb-82, Other Types
2) By Procedure: Diagnostic Procedures, Hybrid PET CT Procedures, Positron Emission Tomography Procedures, Therapeutic Procedures, Beta Emitter Procedures, Alpha Emitter Procedures, Targeted Radiopharmaceutical Therapy
3) By Application: Oncology, Cardiology, Neurology, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose), F-18 NaF (Sodium Fluoride), F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging, Rb-82 for Cardiac PET Stress Testing, Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Ga-68 (Gallium-68)
What Trends Are Influencing Changes In The Positron Emission Tomography (PET) Nuclear Medicine Market?
Leading companies in the positron emission tomography (PET) nuclear medicine market are developing technologically advanced products, such as PET slice scanners, to provide high-resolution images of metabolic activity. A PET slice scanner is a medical imaging device that integrates positron emission tomography (PET) with advanced computing methods to produce detailed, cross-sectional images of metabolic processes within the body, facilitating the detection and monitoring of diseases, especially cancer. For example, in July 2024, Positron Corporation, a US-based nuclear medicine company, introduced the NeuSight PET-CT 3D 64-slice scanner. This NeuSight PET-CT 3D 64-slice scanner establishes a new standard in imaging and diagnostic precision, combining advanced technology with patient comfort and operational efficiency. It is engineered to transform cardiac PET imaging and provides exceptional value and performance at an unmatched price point, making it highly suitable for cardiology and oncology clinical studies. With its superior data acquisition and innovative identification technology, the NeuSight PET-CT enhances scanning speed and accuracy, delivering comprehensive anatomic and functional imaging for studies of the heart, tumors, and brain across various molecular imaging applications.
Who Are The Active Companies Shaping The Positron Emission Tomography (PET) Nuclear Medicine Market?
Major companies operating in the positron emission tomography (pet) nuclear medicine market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Shimadzu Corporation, Toshiba America Medical Systems Inc., Mediso Medical Imaging Systems Ltd., Lantheus Holdings Inc., Jubilant DraxImage Inc., Advanced Accelerator Applications, Eckert & Ziegler Strahlen- und Medizintechnik AG, Cardinal Health, NorthStar Medical Radioisotopes LLC, Bruker Corporation, Digirad Corporation, Neusoft Medical Systems Co. Ltd., Agfa HealthCare NV, Bayer AG, Positron Corporation
Get The Full Positron Emission Tomography (PET) Nuclear Medicine Market Report:
Which Region Dominates The Positron Emission Tomography (PET) Nuclear Medicine Market By Market Share?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Positron Emission Tomography (PET) Nuclear Medicine Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Nuclear Medicine Market 2026, By The Business Research Company
Patient Portal Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-portal-global-market-report
Ocular Hypertension Treatment Market Report
https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report
Captive Portal Market Report
https://www.thebusinessresearchcompany.com/report/captive-portal-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model